Summary
- ACell has filed to raise $75 million from an IPO of its common stock.
- The firm develops and sells various wound care products.
- ACLL has shown strong growth but is feeling the negative effects of the Covid19 pandemic; I believe these effects are likely temporary.
- The IPO appears reasonably valued and is worth considering.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
ACell (ACLL) has filed to raise $75 million from the sale of its common stock, according to an amended registration statement.
The company develops and sells wound treatment systems for various tissue care applications.
ACLL was growing revenue sharply but has since felt the negative effects from the Covid19 pandemic.
The IPO appears reasonably valued and I believe the negative effects from Covid19 will be temporary, although may last through 2020.
Company & Technology
Columbia, Maryland-based ACell was founded to develop proprietary porcine urinary bladder matrix technologies to assist in the reinforcement of soft tissue that has been damaged.
Management is headed by Mr. Patrick McBrayer, who has been with the firm since 2016 and was previously president and Chief Executive Officer of AxioMed Spine until the company's acquisition in 2014.
Below is a brief overview video of abdominal wall repair using the firm's technologies:
